The Academy of Oncology Nurse & Patient Navigators (AONN+) is the largest national specialty organization dedicated to improving patient care and quality of life by defining, enhancing, and promoting the role of oncology nurse and patient navigators. Our organization of over 8,900 members was founded in May 2009 to provide a network for all professionals involved and interested in patient navigation and survivorship care services to better manage the complexities of the cancer care treatment continuum for their patients. We view our organization as one consisting of “professional patient advocates” and, to that end, we support and serve our members.
The Journal of Oncology Navigation & Survivorship (JONS) promotes reliance on evidence-based practices in navigating patients with cancer and their caregivers through diagnosis, treatment, and survivorship. JONS also seeks to strengthen the role of nurse and patient navigators in cancer care by serving as a platform for these professionals to disseminate original research findings, exchange best practices, and find support for their growing community.
The Oncology Nurse-APN/PA (TON) provides coverage of the wide spectrum of oncology-related events, trends, news, therapeutics, diagnostics, organizations, and legislation that directly affect hematology/oncology nurses and advanced practitioners involved in healthcare delivery and product utilization. The scope and coverage include a unique presentation of news and events that are shaping the care of patients with cancer.
Christine Tabery digs deep into the emotional landscape of dealing with cancer as a caregiver to her husband, who has metastatic melanoma, feeling everything he feels just as if it were happening to her. Read More ›
In January 2022, the FDA approved Kimmtrak (tebentafusp-tebn), a novel type of immunotherapy, for the treatment of adults with advanced or spreading uveal melanoma, a rare and aggressive type of melanoma that affects the eye. Kimmtrak is the first drug approved for this type of melanoma. Read More ›
Several immunotherapies known as immune checkpoint inhibitors are available today for patients with melanoma, as well as targeted therapies for patients with a BRAF or MEK gene mutation, but there are no effective treatments approved for patients with metastatic (spreading) or nonresectable (cannot be removed by surgery) melanoma whose disease progressed (got worse) after using an immune checkpoint inhibitor, or a BRAF or MEK inhibitor for those with gene mutations. Read More ›
Diagnosed with melanoma a few weeks after her wedding, Meredith died of the disease 4 months later, at age 35. Her family created Meredith’s Mission for Melanoma, a non-profit organization, to support melanoma research and increase awareness of this deadly cancer. Read More ›